Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES) Save

Date Added
October 11th, 2016
PRO Number
Pro00059594
Researcher
Charles Greenberg

Silhouette
Keywords
Blood Disorders, Drug Studies, Rare Diseases
Summary

Subjects who completed Study ALX0681-C301 (HERCULES) will be given the option to participate in this follow-up study which requires a clinic visit every 6 months for 3 years. Should the subject present with a recurrence of TTP during this time they will be treated with caplacizumab in addition to receiving standard of care treatment.

Institution
MUSC
Recruitment Contact
Lauren Card
843-792-5935
cardl@musc.edu

Change_preferences

-- OR --

Create_login